 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || STI-6643 / Sorrento
Trial completion date, Trial primary completion date, Metastases: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jan 17, 2023
P1, N=100, Recruiting, Sponsor: Sorrento Therapeutics, Inc.
Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Sep 2024 --> Dec 2024
- || STI-6643 / Sorrento
Enrollment change, Trial primary completion date, Metastases: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Sep 26, 2022
P1, N=100, Recruiting, Sponsor: Sorrento Therapeutics, Inc.
Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Sep 2024 --> Dec 2024 N=24 --> 100 | Trial primary completion date: Mar 2024 --> Sep 2024
- | STI-6643 / Sorrento
Trial completion date, Trial primary completion date, Metastases: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jul 5, 2022
P1, N=24, Recruiting, Sponsor: Sorrento Therapeutics, Inc.
N=24 --> 100 | Trial primary completion date: Mar 2024 --> Sep 2024 Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Mar 2022 --> Mar 2024
- | Journal, IO biomarker: A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells. (Pubmed Central) - Jun 8, 2022
Finally, STI-6643 displayed comparable anti-tumor activity to the high-affinity reference clone Hu5F9 in a RAJI-Fluc xenograft tumor model as monotherapy or in combination with anti-CD20 (rituximab) or anti-CD38 (daratumumab) mAbs. These data suggest that STI-6643 possesses the characteristics of an effective therapeutic candidate given its potent anti-tumor activity and low toxicity profile.
- || STI-6643 / Sorrento
Enrollment open, Trial initiation date, Metastases: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 26, 2021
P1, N=24, Recruiting, Sponsor: Sorrento Therapeutics, Inc.
These data suggest that STI-6643 possesses the characteristics of an effective therapeutic candidate given its potent anti-tumor activity and low toxicity profile. Not yet recruiting --> Recruiting | Initiation date: Aug 2021 --> Nov 2021
- || STI-6643 / Sorrento
New P1 trial, Metastases: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - May 25, 2021
P1, N=24, Not yet recruiting, Sponsor: Sorrento Therapeutics, Inc.